Phase 2 Study of TYRA-300 Shows Promise for FGFR3 Altered NMIBC
Tyra Biosciences is conducting Phase 2 study of TYRA-300 targeting FGFR3 alterations in low grade, intermediate risk non-muscle invasive bladder cancer.
Asset / Drug
Drug and asset intelligence for TYRA-300 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.